Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes Three RNAi-Related Patent Applications: Jun 8, 2006

Premium

Title: Therapeutic RNAi Agents for Treating Psoriasis

Number: 20060115455

Filed: Oct. 21, 2005

Lead Inventor: Ken Reed, Benitec

According to the patent application's abstract, the invention "provides compositions and methods suitable for delivering RNAi agents against genetic targets in skin tissues so as to treat psoriasis."


Title: Therapeutic RNAi Agents for Treating Restenosis

Number: 20060115454

Filed: Oct. 14, 2005

Lead Inventor: Linda Couto, Benitec

According to the patent application's abstract, the invention "provides compositions and methods suitable for delivering RNAi agents against genetic targets in vascular and adjacent tissue in vivo so as to treat restenosis."


Title: Apparatus and System Having Dry Gene-Silencing Compositions

Number: 20060115461

Filed: Nov. 18, 2005

Lead Inventor: Barbara Robertson, Dharmacon

The patent application, its abstract states, covers "a reverse-transfection apparatus … for introducing siRNA into a cell to effect gene silencing. Such an apparatus can include a well plate having a well configured for transfecting cells. The well can include a substantially dry gene-silencing composition that has at least a first siRNA which silences a first target gene. The gene-silencing composition can be configured such that the at least first siRNA is capable of being solubilized or suspended in an aqueous medium in an amount sufficient for transfecting cells in the well. Additionally, the at least first siRNA can include a modification or a conjugate. The reverse-transfection apparatus can be provided as a kit or system that additionally includes cells, polynucleotide carriers, reverse transfection reagents, and the like."

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.